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Vuppalanchi et al. The potential for HDS to cause hepatotoxicity is confirmed by a recent report from the Drug Induced Liver Injury Network (DILIN) demonstrating that many types of HDS, particularly those used for bodybuilding, have the capacity for causing liver injury. 5 The DILIN is a multicenter research network in the U.S. developed to study patients with hepatotoxicity due to conventional medications and HDS. Approximately 15% of drug induced liver injury cases ascertained by the DILIN are attributable to HDS, and there now are more than 130 cases of liver injury related to HDS in the DILIN database. The DILIN experience showed that HDS used for nonbodybuilding purposes (e.g., weight loss) are associated with more severe liver injury than is the injury resulting from prescription medications. This is apparent from the finding that 13% of study participants suffering from hepatotoxicity due to non-bodybuilding HDS required transplantation as compared to only 3% of those with conventional medication associated liver injury (P< 0.001). 5 Importantly, the DILIN was not designed as a population-based study, so that the true incidence of liver injury in the U.S. due to herbal products is yet to be established This
notwithstanding, the DILIN's findings are particularly important against the backdrop of the current regulatory environment for HDS, which neither promotes nor mandates research on their safety or efficacy. A survey of the literature indicates that HDS-related hepatotoxicity is indeed a world-wide problem. Data from a Spanish Liver Toxicity Registry showed that HDS products accounted for 2% of all cases of identified liver injury between 1994 and 2006 and that they ranked as the 10 th most common therapeutic group. 7 Because of the wide use of HDS in China, India, other countries in Southeast Asia as well as Africa and Central America, the incidence in these countries could be much higher than it is in western countries. This likelihood is supported by prospective studies from Korea and Singapore that reported HDS as being responsible for 73% and 71%, respectively, of all their identified cases of hepatotoxicity. 8, 9 The widespread use of HDS, the permissive U.S. regulatory environment for dietary supplements, and the potential toxicity attributable to HDS give context to the need for research in this area. Little systematic investigation has been performed and an understanding of the hepatotoxic potential of HDS is limited to observational studies. Moreover, protection of the public from potentially injurious effects of HDS depends upon the FDA's ability to identify harmful products or ingredients after release to the market, and their recommendation that they then be removed from use.
The approach to studying toxicity attributable to HDS is confounded by many factors. These factors, ostensibly barriers to research, give some direction for future studies to evaluate hepatotoxicity due to HDS.
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The DILIN aims to better understand hepatotoxicity associated with HDS. As its first endeavor, it established a repository for HDS that have been linked to hepatotoxicity. Many that were implicated in liver injury have been retrieved from patients and are available for study by contacting the Chairman of the DILIN HDS Subcommittee (VN, corresponding author). As of October 1, 2014, 318 HDS products comprise this repository, collected from 119 patients, enrolled at 10 DILIN clinical sites. Already, the repository has proven itself to be an important resource for exploring the hepatotoxic potential of certain ingredients. For example, in a detailed product analysis involving green tea extracts, about 40% of products found to contain green extracts did not identify its presence on the label 12 . However, no relationship was found between the concentration of green tea extract and the severity of liver injury, suggesting either that idiosyncrasy accounted for the injury or that another ingredient was responsible.
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Collaboration with scientists interested in the chemical composition of botanical products will add future value to this repository by providing the means to seek the injurious ingredients.
Arguably, the greatest challenge in studying hepatotoxicity associated with HDS lies in the complexity of the products, making difficult the identification of the precise ingredient or combination of ingredients responsible for the injury. The confident identification of a toxic culprit will require labor intensive chemical dissection of HDS into their component parts and testing each individual and combination of ingredients for potential toxicity. This task will, however, be formidable for even the most well-funded and resourceful laboratories.
The lack of a conventional classification scheme or nomenclature for HDS complicates scientific investigation, because commercial HDS products may contain multiple constituents and combinations of ingredients. Thus, the DILIN has developed a nomenclature for HDS based upon their primary purported marketed benefit. A structured classification for HDS will allow comparison of liver injury cases attributed to the same or similar products and identify characteristic clinical patterns of injury, unique to a given type of product or ingredient. This M A N U S C R I P T
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schema is founded upon the frequency with which products were implicated by the DILIN (Table   1) .
Much is yet to be learned about behavioral factors that contribute to toxicity resulting from HDS. Patterns of use and overuse have not been studied and little is known of where consumers obtain information on use of products. The DILIN study offers the opportunity to expand knowledge about these features through the extensive clinical and behavioral data being collected.
Claims that HDS "stimulate", "maintain", "support", "regulate", "cleanse" or "promote"
health will continue to entice consumers. However, given the now proven hepatotoxic potential of some types of products, it is the responsibility of health care providers and physician scientists to sound the alarm and to create a research agenda to mitigate liver injury. In 
